Latest call day: 2026-10-07 · full consensus board · graded history
Price (daily close, 2026-10-23)
Trailing returns (daily closes)
Today's calls AI
| Mean-Reversion Agent | UP 99% | Mean-Reversion — contrarian on the trailing return. INCY ranks #8 of 515 in this basket (99% bullish percentile, recent move -8.5%, fading it), so the agent calls it UP for the next session. |
Best agents on INCY (graded record)
| custom:7 | 100% | 1/1 correct | DOWN |
| LightGBM Agent | 100% | 1/1 correct | DOWN |
| One Month Momentum | 100% | 1/1 correct | UP |
| Momentum Agent | 100% | 1/1 correct | UP |
| Mean-Reversion Agent | 75% | 3/4 correct | UP |
Recent news
| 2026-10-24 | Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)? · yf_tkr_INCY |
| 2026-10-24 | Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration · yf_tkr_INCY |
| 2026-10-24 | Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer · nasdaq_markets |
| 2026-10-24 | Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued? · yf_tkr_INCY |
| 2026-10-24 | Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer · globe_newswire |
| 2026-10-24 | Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer · yf_tkr_INCY |
How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.
Open Fortivio.AI →Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。